<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=7559&amp;modal=1&amp;valnames=primary_outcome&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="412742" class="table-">
                
                <td>June 10, 2022, 9:30 a.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            None
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="166204" class="table-">
                
                <td>Nov. 16, 2021, 6:30 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Cohort 1: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohort 2: Groups 4, 5 and 6: Antibody Titer as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohorts 1: Antibody Titer as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S;Cohorts 1: Serological Response to Vaccination as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Cohort 1: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohort 2: Groups 4, 5 and 6: Antibody Titer as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohorts 1: Antibody Titer as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S;Cohorts 1: Serological Response to Vaccination as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
June 10, 2022, 9:30 a.m.	usa	None
Nov. 16, 2021, 6:30 p.m.	usa	Cohort 1: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohort 2: Groups 4, 5 and 6: Antibody Titer as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohorts 1: Antibody Titer as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S;Cohorts 1: Serological Response to Vaccination as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S	Cohort 1: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Groups 1, 2 and 3: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with Ad26.COV2.S;Cohort 1: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 28 days After Primary Vaccination with Ad26.COV2.S;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Antibody Titers as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohort 2: Groups 4, 5 and 6: Antibody Titer as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Antibody Titers as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Groups 4, 5 and 6: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern, 14 Days After Ad26.COV2.S Booster Vaccination after Completing Primary Vaccination with BNT162b2;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Leading Variant of High Consequence or Concern in Pfizer BNT162b2 External Samples;Cohort 2: Serological Response to Vaccination as Measured by VNA Titers Against the Original Strain, in Pfizer BNT162b2 External Samples;Cohorts 1: Antibody Titer as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S;Cohorts 1: Serological Response to Vaccination as Measured by VNA Titers, 28 Days After Primary Vaccination with Ad26.COV2.S